Literature DB >> 25421367

10th anniversary of the Austrian MDS Platform: aims and ongoing projects.

Sonja Burgstaller1, Peter Bettelheim, Otto Krieger, Sigrid Machherndl-Spandl, Thomas Nösslinger, Lisa Pleyer, Heinz Sill, Wolfgang R Sperr, Reinhard Stauder, Peter Valent, Michael Pfeilstöcker.   

Abstract

The Austrian myelodysplastic syndromes (MDS) Platform was founded as a national working group in 2003 to initiate and coordinate common projects in the field. The incidence of MDS in Austria is approximately 400-500 new MDS cases per year. The overall low number of MDS patients underlines the importance of a national initiative to concentrate knowledge at certain specialized centres, where treatment of these patients mainly takes place. Clinical trials as well as basic research are facilitated by the cooperation of university and non-university hospitals. Other objectives are the generation of therapeutic standards, organization of meetings to spread this information to physicians and patients as well as promoting patient-support groups. Cooperation with international working groups is another important aim of the Platform. The 10th anniversary of the Austrian MDS Platform was organized as a meeting for all interested physicians throughout Austria providing an update on the disease and ongoing projects.

Entities:  

Mesh:

Year:  2014        PMID: 25421367     DOI: 10.1007/s00508-014-0627-0

Source DB:  PubMed          Journal:  Wien Klin Wochenschr        ISSN: 0043-5325            Impact factor:   1.704


  28 in total

Review 1.  Therapy-related myeloid neoplasms: pathobiology and clinical characteristics.

Authors:  H Sill; W Olipitz; A Zebisch; E Schulz; A Wölfler
Journal:  Br J Pharmacol       Date:  2011-02       Impact factor: 8.739

2.  Lenalidomide in the myelodysplastic syndrome with chromosome 5q deletion.

Authors:  Alan List; Gordon Dewald; John Bennett; Aristotle Giagounidis; Azra Raza; Eric Feldman; Bayard Powell; Peter Greenberg; Deborah Thomas; Richard Stone; Craig Reeder; Kenton Wride; John Patin; Michele Schmidt; Jerome Zeldis; Robert Knight
Journal:  N Engl J Med       Date:  2006-10-05       Impact factor: 91.245

3.  Outcome of high-risk myelodysplastic syndrome after azacitidine treatment failure.

Authors:  Thomas Prébet; Steven D Gore; Benjamin Esterni; Claude Gardin; Raphael Itzykson; Sylvain Thepot; François Dreyfus; Odile Beyne Rauzy; Christian Recher; Lionel Adès; Bruno Quesnel; C L Beach; Pierre Fenaux; Norbert Vey
Journal:  J Clin Oncol       Date:  2011-07-25       Impact factor: 44.544

4.  Azacitidine in CMML: matched-pair analyses of daily-life patients reveal modest effects on clinical course and survival.

Authors:  Lisa Pleyer; Ulrich Germing; Wolfgang R Sperr; Werner Linkesch; Sonja Burgstaller; Reinhard Stauder; Michael Girschikofsky; Martin Schreder; Michael Pfeilstocker; Alois Lang; Thamer Sliwa; Dietmar Geissler; Konstantin Schlick; Gudrun Placher-Sorko; Georg Theiler; Josef Thaler; Martina Mitrovic; Daniel Neureiter; Peter Valent; Richard Greil
Journal:  Leuk Res       Date:  2014-01-18       Impact factor: 3.156

5.  Comorbidity as prognostic variable in MDS: comparative evaluation of the HCT-CI and CCI in a core dataset of 419 patients of the Austrian MDS Study Group.

Authors:  W R Sperr; F Wimazal; M Kundi; C Baumgartner; T Nösslinger; A Makrai; R Stauder; O Krieger; M Pfeilstöcker; P Valent
Journal:  Ann Oncol       Date:  2009-07-15       Impact factor: 32.976

6.  Prognostic impact of age and gender in 897 untreated patients with primary myelodysplastic syndromes.

Authors:  T Nösslinger; H Tüchler; U Germing; W R Sperr; O Krieger; D Haase; M Lübbert; R Stauder; A Giagounidis; P Valent; M Pfeilstöcker
Journal:  Ann Oncol       Date:  2009-07-15       Impact factor: 32.976

7.  New insights into the prognostic impact of the karyotype in MDS and correlation with subtypes: evidence from a core dataset of 2124 patients.

Authors:  Detlef Haase; Ulrich Germing; Julie Schanz; Michael Pfeilstöcker; Thomas Nösslinger; Barbara Hildebrandt; Andrea Kundgen; Michael Lübbert; Regina Kunzmann; Aristoteles A N Giagounidis; Carlo Aul; Lorenz Trümper; Otto Krieger; Reinhard Stauder; Thomas H Müller; Friedrich Wimazal; Peter Valent; Christa Fonatsch; Christian Steidl
Journal:  Blood       Date:  2007-08-28       Impact factor: 22.113

8.  Proposed score for survival of patients with myelodysplastic syndromes.

Authors:  Wolfgang R Sperr; Michael Kundi; Friedrich Wimazal; Thomas Nösslinger; Anabel Schönmetzler-Makrai; Reinhard Stauder; Otto Krieger; Judith Neukirchen; Ulrich Germing; Michael Pfeilstöcker; Peter Valent
Journal:  Eur J Clin Invest       Date:  2013-09-18       Impact factor: 4.686

9.  A decision analysis of allogeneic bone marrow transplantation for the myelodysplastic syndromes: delayed transplantation for low-risk myelodysplasia is associated with improved outcome.

Authors:  Corey S Cutler; Stephanie J Lee; Peter Greenberg; H Joachim Deeg; Waleska S Pérez; Claudio Anasetti; Brian J Bolwell; Mitchell S Cairo; Robert Peter Gale; John P Klein; Hillard M Lazarus; Jane L Liesveld; Philip L McCarthy; Gustavo A Milone; J Douglas Rizzo; Kirk R Schultz; Michael E Trigg; Armand Keating; Daniel J Weisdorf; Joseph H Antin; Mary M Horowitz
Journal:  Blood       Date:  2004-03-23       Impact factor: 22.113

10.  Iron overload in myelodysplastic syndromes (MDS) - diagnosis, management, and response criteria: a proposal of the Austrian MDS platform.

Authors:  P Valent; O Krieger; R Stauder; F Wimazal; T Nösslinger; W R Sperr; H Sill; P Bettelheim; M Pfeilstöcker
Journal:  Eur J Clin Invest       Date:  2008-01-24       Impact factor: 4.686

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.